Cyclogyl®

Cyclopentolate 0.5%, 1%, 2% · ophthalmic solution

Mydriatics/Cycloplegics

• CNS disturbances: Especially likely in younger age groups and with the stronger solutions, but possible at any age.
• Concentration-dependent CNS risk: Psychotic and behavioral reactions occur mainly in children and especially with 2%; a 2022 mini review recommends avoiding 2% and pairing a lower strength with phenylephrine instead.
• Infant systemic absorption: Infants are especially prone to CNS and cardiopulmonary effects; use one drop of 0.5% per eye, apply pressure over the nasolacrimal sac for two to three minutes, and observe for at least 30 minutes.
• IOP and angle closure: Mydriatics may transiently raise intraocular pressure, and untreated narrow angle glaucoma or anatomically narrow angles may be susceptible to angle closure after instillation.
• Down syndrome: Caution when considering use.
• Preterm infant feeding: Feeding intolerance and necrotizing enterocolitis have been reported after ophthalmic use, causality not established; withhold feeding for 4 hours after examination.
• Cholinergic drug interaction: May interfere with the ocular antihypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors.
• Route restriction: Topical ophthalmic use only, not for injection.